OR WAIT 15 SECS
Researchers will focus on pterostilbene’s connection to breast, ovarian and uterine cancers.
City of Hope (Duarte, CA) will soon begin studying the effects of pterostilbene on the treatment of ovarian, uterine and breast cancer at its Beckman Research Institute. The comprehensive cancer research and treatment center has partnered with ChromaDex Corp. (Irvine, CA), who will supply its pTeroPure brand pterostilbene for use in preclinical in vitro and mouse model experiments designed to determine its potential therapeutic treatment benefits.
Past in vitro studies have suggested that pterostilbene, an antioxidant primarily found in blueberries, is inherently able to prevent the growth of several common cancer cell malignancies with negligible toxicity. According to ChromaDex, earlier studies have acknowledged pterostilbene’s pronounced bioavailability in comparison to other stilbene compounds, though its mechanisms of actions in humans still warrant further study.
“By providing materials to BRICOH for preclinical studies, we will learn more about the potential of pTeroPure's application in cancer,” commented Frank Jaksch, ChromaDex founder and CEO. “This relationship will complement our ongoing partnership with UC-Irvine, where we are supporting ongoing research on pTeroPure’s use for non-melanoma skin cancer.”